Sonoma Pharmaceuticals (SNOA)
(Delayed Data from NSDQ)
$0.24 USD
+0.01 (5.08%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.24 0.00 (-0.83%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Sonoma Pharmaceuticals, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 4 | 7 | 4 | 4 |
Receivables | 3 | 3 | 2 | 3 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 3 | 3 | 3 | 2 |
Other Current Assets | 4 | 5 | 4 | 3 | 2 |
Total Current Assets | 13 | 14 | 16 | 13 | 12 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 1 | 1 | 1 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 15 | 16 | 19 | 15 | 15 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 1 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 2 | 1 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Total Current Liabilities | 4 | 4 | 6 | 4 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 4 | 4 | 3 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 8 | 10 | 10 | 6 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 203 | 201 | 197 | 189 | 187 |
Retained Earnings | -194 | -190 | -184 | -179 | -172 |
Other Equity | -3 | -3 | -4 | -5 | -6 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 6 | 8 | 9 | 5 | 9 |
Total Liabilities & Shareholder's Equity | 15 | 16 | 19 | 15 | 15 |
Total Common Equity | 6 | 8 | 9 | 5 | 9 |
Shares Outstanding | 15.60 | 4.60 | 3.10 | 2.00 | 1.70 |
Book Value Per Share | 0.39 | 1.73 | 2.81 | 2.68 | 5.12 |
Fiscal Year End for Sonoma Pharmaceuticals, Inc falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 3 | 2 | 2 | 4 |
Receivables | 3 | 3 | 3 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 3 | 3 | 3 | 3 |
Other Current Assets | 3 | 4 | 4 | 5 | 5 |
Total Current Assets | 12 | 13 | 13 | 12 | 14 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 1 | 1 | 1 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 14 | 15 | 15 | 14 | 16 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 2 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 4 | 3 | 3 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 5 | 4 | 4 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 9 | 8 | 8 | 9 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 204 | 203 | 203 | 201 | 201 |
Retained Earnings | -195 | -194 | -193 | -192 | -191 |
Other Equity | -4 | -3 | -3 | -3 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 5 | 6 | 7 | 6 | 7 |
Total Liabilities & Shareholder's Equity | 14 | 15 | 15 | 14 | 16 |
Total Common Equity | 5 | 6 | 7 | 6 | 7 |
Shares Outstanding | 19.00 | 15.60 | 13.60 | 5.10 | 5.10 |
Book Value Per Share | 0.26 | 0.39 | 0.49 | 1.11 | 1.42 |